1. Which 2 treatments for patients with multiple sclerosis are considered similar in efficacy, and have proven to reduce relapse rates by approximately one-third over the course of 2 years?

2. RT is a 46-year-old female with a 15-year history of relapsing remitting multiple sclerosis. She has been on glatiramer acetate for the last 3 years but her neurologic symptoms have progressed, and she has continued to develop new lesions which are visible on magnetic resonance imaging. Her past medical history also includes dyslipidemia, type 2 diabetes mellitus, and a recent stroke. What is the best course of action at this time?

3. Which of the following emerging therapies for patients with multiple sclerosis is NOT an orally acting agent?

4. The ALLEGRO study was a phase III trial demonstrating that patients with relapse remitting multiple sclerosis who were treated with which medication experienced statistically significant reductions in annualized relapse rate and disability progression, compared to placebo?

5. Which of the following models of neurodegeneration suggests that chronic inflammatory demyelination leads to secondary axonal swelling and degeneration in patients with multiple sclerosis?

6. Menstrual irregularities, injection site reactions, depression, and flu-like symptoms are common adverse effects associated with:

7. One important risk factor for patients with multiple sclerosis who also have progressive multifocal leukoencephalopathy and who are receiving natalizumab therapy is the duration of their therapy being longer than:

8. Which of the following is NOT specified by the “Tysabri Outreach: Unified Commitment to Health (TOUCH)” program for natalizumab?

9. Fingolimod is a pregnancy category _____ medication.

10. PN is a 32-year-old MS patient who has been treated with interferon β therapy for the past 2 years. A recent magnetic resonance imaging scan revealed 2 new active enhancing lesions. Upon further evaluation, PN admitted to being noncompliant with drug therapy because of injection-site pain. His managed care pharmacist can suggest all of the following strategies to help alleviate pain and improve compliance EXCEPT:

« Return to Activity